Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP7 | P09237 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL29215668 | 0.83 | SLC1A3 (0.45) | GRIK1GRIK2MMP2MMP3MMP7 | |
| SCHEMBL13710824 | 0.81 | SLC1A3 (0.37) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10308328 | 0.81 | SLC1A3 (0.37) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27542515 | 0.81 | MMP2 (0.41) | GRIK1GRIK2MMP2MMP3MMP7 | |
| SCHEMBL4798136 | 0.79 | SLC1A3 (0.45) | GRIK1GRIK2MMP2MMP3MMP7 | |
| SCHEMBL2987274 | 0.79 | SLC1A3 (0.45) | GRIK1GRIK2MMP2MMP3MMP7 | |
| SCHEMBL3579874 | 0.79 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1EPHX1ECE1 | |
| SCHEMBL2987273 | 0.79 | SLC1A3 (0.45) | GRIK1GRIK2MMP2MMP3MMP7 | |
| SCHEMBL25832508 | 0.79 | MMP2 (0.36) | GRIK1GRIK2MMP2MMP3MMP7 | |
| Apronal SCHEMBL662209 | 0.78 | MMP2 (0.37) | GRIK1GRIK2MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200110-B1 | IN VIVO INDUCTION FOR ENHANCED FUNCTION OF ISOLATED HEPATOCYTES | ORGANOGENESIS INC (US) | 2014-04-23 | — | — | EP | claimed |
| US-20090005437-A1 | Alpha-Ketoglutarates and Their Use as Therapeutic Agents | UNIVERSITY OF STRATHCLYDE (GB) | 2009-01-01 | — | — | US | claimed |
| US-7169607-B2 | In vivo induction for enhanced function of isolated hepatocytes | ORGANOGENESIS, INC (US) | 2007-01-30 | — | — | US | claimed |
| US-6699716-B2 | HEPATOCYTES THAT HAVE INCREASED DETOXIFICATION ENZYME ACTIVITY WHEN ISOLATED FROM A LIVER OF A DONOR THAT HAD BEEN ADMINISTERED AT LEAST ONE INDUCTION AGENT PRIOR ISOLATION OF HEPATOCYTE CELLS. | ORGANOGENESIS INC. | 2004-03-02 | — | — | US | claimed |
| US-20040005303-A1 | In vivo induction for enhanced function of isolated hepatocytes | ORGANOGENESIS, INC. | 2004-01-08 | — | — | US | claimed |
| US-20020085995-A1 | In vivo induction for enhanced function of isolated hepatocytes | SILICON VALLEY BANK | 2002-07-04 | — | — | US | claimed |
| US-6394812-B1 | LIVER CELL CULTURE | ORGANOGENESIS INC. | 2002-05-28 | — | — | US | claimed |
| CN-1273581-A | Process and reagent for N-alkylation of ureides | TARO PHARMA IND (IL) | 2000-11-15 | — | — | CN | claimed |
| US-11311567-B2 | Cytochrome P450 enzyme complexes and methods of treatment using the same | INNOVATION HAMMER, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311566-B2 | Cytochrome P450 enzyme complexes and methods of treatment using the same | INNOVATION HAMMER, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| CN-113038933-A | Oral pharmaceutical preparation containing ibuprofen | SS制药株式会社 | 2021-06-25 | — | — | CN | disclosed |
| US-20210015838-A1 | Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same | INNOVATION HAMMER LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-20200384008-A1 | Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same | INNOVATION HAMMER LLC (US) | 2020-12-10 | — | — | US | disclosed |
| US-10786524-B2 | Cytochrome P450 enzyme complexes and methods of treatment using the same | INNOVATION HAMMER LLC (US) | 2020-09-29 | — | — | US | disclosed |
| EP-1015030-A2 | PHOTOCHEMOTHERAPEUTIC COMPOSITIONS | Photocure AS (NO) | 2000-07-05 | — | — | EP | disclosed |
| US-6020288-A | PLANT GROWTH AGENT | NONOMURA ARTHUR M (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999012417-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CYTOCHROME P450 IN PLANTS | NONOMURA ARTHUR M (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1998030242-A2 | PHOTOCHEMOTHERAPEUTIC COMPOSITIONS | PHOTOCURE AS (NO) | 1998-07-16 | — | — | WO | disclosed |
| WO-1996001426-A1 | HEPATOCYTE TEST KIT | W.R. GRACE & CO.-CONN. (US) | 1996-01-18 | — | — | WO | disclosed |
| US-5008388-A | For treatment of various types of anemia | HUHTAMAKI OY (FI) | 1991-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005437-A1 | Alpha-Ketoglutarates and Their Use as Therapeutic Agents | HIF1A, HIF1AN, EGLN3 | GRIK1 1917/4885GRIK2 2622/4885MMP2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.